NOAC vs ASA: Breakthrough Findings in Post-TAVI Care

Evaluating Antithrombotic Therapy After TAVI

Transcatheter aortic valve implantation has revolutionized the management of severe aortic stenosis. Clinicians now perform this procedure in younger and lower-risk patients. Consequently, ensuring long-term bioprosthetic valve durability has become a paramount clinical objective. Subclinical leaflet thrombosis often causes early valve degeneration and increases thromboembolic risk. Therefore, selecting the optimal antithrombotic therapy after TAVI remains critical for practicing cardiologists. The multicenter ACASA-TAVI randomized trial directly evaluated whether a non-vitamin K antagonist oral anticoagulant provides superior protection compared to acetylsalicylic acid monotherapy.

Key Efficacy Findings from the ACASA-TAVI Trial

The ACASA-TAVI trial enrolled 360 patients across three high-volume centers in Norway. Investigators randomized participants to receive either 12 months of NOAC monotherapy or ASA monotherapy. Specifically, researchers assessed valve leaflet thrombosis using 4-dimensional cardiac computed tomography at 12 months. Blinded core laboratory analysts measured hypoattenuated leaflet thickening to determine treatment efficacy.

Ultimately, the trial demonstrated a striking reduction in leaflet thrombosis among patients receiving NOAC monotherapy. Only 16.2% of patients in the NOAC arm developed hypoattenuated leaflet thickening compared to 28.6% in the aspirin arm. This represents a significant 45% relative risk reduction. Thus, oral factor Xa inhibition markedly suppresses subclinical thrombus formation on bioprosthetic leaflets.

Safety Profile and Clinical Implications

Safety remains equally vital when selecting antithrombotic regimens for elderly cardiac patients. The primary safety endpoint comprised major bleeding, thromboembolic complications, and all-cause mortality at 12 months. Notably, NOAC monotherapy met the criteria for noninferiority regarding composite safety outcomes. Adverse safety events occurred in 7.5% of the NOAC group versus 10.6% of the aspirin group.

Furthermore, life-threatening or fatal bleeding events occurred exclusively in the aspirin cohort. Therefore, NOAC monotherapy offers potent leaflet protection without elevating bleeding hazards. In conclusion, these robust data provide compelling evidence to reconsider routine antiplatelet monotherapy post-procedure, particularly as transcatheter interventions expand to younger cohorts.

Frequently Asked Questions

Q1: What did the ACASA-TAVI trial demonstrate regarding valve thrombosis?

The trial showed that 12 months of NOAC monotherapy significantly reduced subclinical leaflet thrombosis compared to aspirin monotherapy, achieving a 45% relative risk reduction without compromising safety.

Q2: Did NOAC therapy increase bleeding complications compared to aspirin?

No, the NOAC regimen proved noninferior for composite safety outcomes. In fact, adverse safety events and major bleeding occurred numerically less frequently in the NOAC group.

Q3: How do these findings impact clinical practice for Indian interventional cardiologists?

These findings suggest that NOAC monotherapy may better preserve valve durability in younger TAVI recipients, providing strong evidence to guide antithrombotic selection in routine post-procedural care.

References

1. Dodgson CS et al. Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant: The ACASA-TAVI Randomized Clinical Trial. JAMA. 2026 Aug 30. doi: 10.1001/jama.2026.17036. PMID: 42669043.
2. Jørgensen TH et al. Short-Term DOAC Therapy and Subclinical Leaflet Thickening Post TAVR: The NOTION-4 Trial. J Am Coll Cardiol. 2026; doi:10.1016/j.jacc.2026.08.015.
3. Dangas GD et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. N Engl J Med. 2020;382(2):120-129.